| scholarly article | Q13442814 |
| P2093 | author name string | Angelika Banzhoff | |
| Jeffrey J Stoddard | |||
| P2860 | cites work | Vaccines for preventing influenza in healthy children | Q24243174 |
| The annual impact of seasonal influenza in the US: Measuring disease burden and costs | Q29030744 | ||
| MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. | Q30380647 | ||
| Severe hospitalised 2009 pandemic influenza A(H1N1) cases in France, 1 July-15 November 2009. | Q30384606 | ||
| Surveillance of hospitalisations for 2009 pandemic influenza A(H1N1) in the Netherlands, 5 June - 31 December 2009. | Q30384609 | ||
| Update: influenza activity - United States, 2009-10 season | Q30392070 | ||
| Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) infections | Q30393399 | ||
| Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study | Q30395522 | ||
| [Excess mortality in Spain during transmission of pandemic influenza in 2009]. | Q30398110 | ||
| Viral shedding duration of pandemic influenza A H1N1 virus during an elementary school outbreak--Pennsylvania, May-June 2009. | Q30399982 | ||
| Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy | Q30402238 | ||
| Assessing the burden of paediatric influenza in Europe: the European Paediatric Influenza Analysis (EPIA) project | Q33931458 | ||
| Health benefits, risks, and cost-effectiveness of influenza vaccination of children | Q35792094 | ||
| Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation | Q37392434 | ||
| Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom | Q38494697 | ||
| Clinical features of hospitalised children with 2009 H1N1 influenza virus infection | Q40353080 | ||
| Socioeconomic impact of influenza on healthy children and their families | Q40548573 | ||
| MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination | Q43258765 | ||
| Incidence of influenza-related hospitalizations in different age groups of children in Finland: a 16-year study | Q43510062 | ||
| Influenza-related hospitalisations among children aged less than 5 years old in the Basque Country, Spain: a 3-year study (July 2001-June 2004). | Q43614574 | ||
| Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children | Q43626562 | ||
| Hospital utilization and costs among children with influenza, 2003. | Q43805787 | ||
| A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis | Q44392994 | ||
| Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant | Q44543899 | ||
| Pharmacoeconomic evaluation of the MF59--adjuvanted influenza vaccine in the elderly population in Italy. | Q44764477 | ||
| High costs of influenza: Direct medical costs of influenza disease in young children | Q44816877 | ||
| Influenza-associated pediatric deaths--United States, September 2010-August 2011. | Q46045197 | ||
| Economic impact of community-acquired and nosocomial lower respiratory tract infections in young children in Germany | Q47777594 | ||
| Burden of influenza in children in the community | Q47924586 | ||
| Prospective population-based study of viral lower respiratory tract infections in children under 3 years of age (the PRI.DE study). | Q47925908 | ||
| The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents. | Q55041616 | ||
| A Paradigm for the Control of Influenza | Q82203629 | ||
| Oil-in-water emulsion adjuvant with influenza vaccine in young children | Q85087747 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | public health | Q189603 |
| influenza vaccine | Q383260 | ||
| P304 | page(s) | 398-402 | |
| P577 | publication date | 2012-02-13 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Effective influenza vaccines for children: a critical unmet medical need and a public health priority | |
| P478 | volume | 8 |
| Q40691072 | A genetically adjuvanted influenza B virus vector increases immunogenicity and protective efficacy in mice |
| Q37616332 | Infants and the seasonal influenza vaccine. A global perspective on safety, effectiveness, and alternate forms of protection |
| Q30375872 | Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine |
| Q50024815 | MF59-adjuvanted influenza vaccine (FLUAD®) elicits higher immune responses than a non-adjuvanted influenza vaccine (Fluzone®): A randomized, multicenter, Phase III pediatric trial in Mexico |
| Q40238572 | Medicinal prophylaxis during intensified immunosuppression in children and adolescents : part 2 |
| Q43497830 | Perspectives on vaccination in adults |
Search more.